CELLECTAR BIOSC Stock Price, News & Analysis

CLRBZ is a symbol associated with Cellectar Biosciences, Inc., which, according to recent company disclosures, is a late-stage clinical biopharmaceutical and radiopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. Cellectar Biosciences is listed on NASDAQ under the symbol CLRB, and its work centers on targeted radiotherapeutics and radioconjugates for both hematologic malignancies and solid tumors.

The company describes its core objective as leveraging a proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, also referred to in some disclosures as a phospholipid ether platform or phospholipid radioconjugate (PRC) technology. This platform is intended to enable cancer cell-targeting treatments that aim to deliver improved efficacy and better safety by reducing off-target effects. Cellectar reports that this platform has demonstrated delivery of a variety of isotopes directly to tumor cells across a broad range of cancers.

Therapeutic Focus and Pipeline

Cellectar’s publicly described pipeline is built around several radiotherapeutic candidates. Its lead asset, iopofosine I 131, is characterized as a PDC designed to provide targeted delivery of iodine-131 for the treatment of hematologic and solid tumor cancers. Company materials state that iopofosine I 131 has been studied in Phase 2b trials in relapsed or refractory Waldenstrom’s macroglobulinemia (WM), multiple myeloma, non-Hodgkin’s lymphomas, and central nervous system lymphoma, as well as in the CLOVER-2 Phase 1b study in pediatric high-grade gliomas. Iopofosine I 131 is described as a potential first-in-class, novel cancer-targeting radioconjugate monotherapy.

Beyond iopofosine, Cellectar highlights additional programs built on the same phospholipid-based targeting concept. CLR 121125 (CLR 125) is described as an iodine-125 Auger-emitting program targeting solid tumors, with specific references in company news to triple-negative breast cancer, lung cancer, and colorectal cancer. CLR 121225 (CLR 225) is presented as an actinium-225 based program targeting solid tumors with significant unmet need, such as pancreatic ductal adenocarcinoma. Company disclosures also refer to proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Regulatory Designations and Development Pathways

Cellectar reports that iopofosine I 131 has received multiple regulatory designations. In the United States, company announcements state that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy, multiple Orphan Drug, Rare Pediatric Disease, and Fast Track designations for various cancer indications, including Waldenstrom’s macroglobulinemia and pediatric high-grade glioma. In Europe, the European Medicines Agency (EMA) has granted PRIME and orphan drug designations for WM. The company has also disclosed advice from the EMA’s Scientific Advice Working Party indicating that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in certain WM patient populations could be acceptable.

According to recent corporate updates, Cellectar’s development activities include Phase 2b work in WM, a Phase 1b dose and regimen optimization study in pediatric high-grade glioma (CLOVER-2), and preparations for Phase 1 or Phase 1b studies for CLR 125 in triple-negative breast cancer and CLR 225 in pancreatic cancer. The company also notes that it has entered into supply agreements for key radioisotopes, including actinium-225 and astatine-211, to support its targeted alpha therapy and PRC pipeline.

Technology Platform

The company’s disclosures emphasize its phospholipid ether-based targeting platform. Cellectar states that this technology is designed to deliver radioisotopes directly to tumor cells and, in the case of CLR 225, to target lipid rafts in hypoxic tumor environments such as pancreatic ductal adenocarcinoma. Preclinical data described by the company for CLR 225 in pancreatic cancer xenograft models indicate inhibition of tumor growth or reduction in tumor volume, along with favorable biodistribution and tolerability in animal studies.

Clinical Areas and Indications

Across its programs, Cellectar focuses on cancers with significant unmet medical need. These include:

• Waldenstrom’s macroglobulinemia (WM): a B-cell malignancy for which the company is pursuing regulatory pathways in both the U.S. and Europe for iopofosine I 131, particularly in patients who are refractory after Bruton Tyrosine Kinase inhibitor therapy.
• Pediatric high-grade gliomas: aggressive brain and central nervous system tumors in children, adolescents, and young adults, where iopofosine I 131 is being evaluated in the CLOVER-2 Phase 1b study.
• Triple-negative breast cancer (TNBC): an aggressive subtype of breast cancer for which CLR 125 is being developed as an Auger-emitting radiotherapeutic candidate.
• Pancreatic ductal adenocarcinoma (PDAC): a form of pancreatic cancer for which CLR 225 has shown preclinical activity in xenograft models.
• Other solid tumors: including lung and colorectal cancers, described as potential targets for CLR 125 and CLR 225 in company communications.

Collaborations and Supply Agreements

Cellectar has reported entering into research and development collaborations and clinical research partnerships to support its trials. The company has announced a partnership with Evestia Clinical, a contract research organization, to provide CRO services for the Phase 1b study of CLR 125 in triple-negative breast cancer. It has also disclosed supply agreements with isotope manufacturers, including Ionetix and ITM Isotope Technologies Munich, for actinium-225 and astatine-211 to support its actinium-based and alpha-emitting radiotherapeutic programs.

Regulatory and Clinical Strategy

Company statements outline a regulatory strategy that includes pursuing conditional marketing authorization in Europe for iopofosine I 131 in WM and an accelerated approval pathway in the United States, supported by Phase 2b data and confirmatory trial planning. In pediatric high-grade glioma, the company highlights the potential eligibility for a Pediatric Review Voucher upon approval of iopofosine I 131. For its early-stage programs CLR 125 and CLR 225, Cellectar describes a progression from preclinical studies and IND-enabling work into dose-finding and first-in-human clinical trials.

Overall, CLRBZ is tied to a company that positions itself, in its own disclosures, as a late-stage clinical radiopharmaceutical and biotechnology developer focused on phospholipid-based, tumor-targeting radiotherapeutics and radioconjugates for difficult-to-treat cancers.